PMID- 22029001
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20231104
IS  - 2230-9500 (Electronic)
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Linking)
VI  - 15
IP  - 4
DP  - 2011 Oct
TI  - Choosing a gliptin.
PG  - 298-308
LID - 10.4103/2230-8210.85583 [doi]
AB  - The treatment of type 2 diabetes mellitus (T2DM) has included the use of 
      metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over 
      since years. This remains, despite the knowledge that the combination results in 
      a progressive decline in [beta]-cell function and by 3 years up to 50% of 
      diabetic patients can require an additional pharmacological agent to maintain the 
      glycosylated hemoglobin (HbA1c) <7.0% (UKPDS). Gliptins represent a novel class 
      of agents that improve beta cell health and suppress glucagon, resulting in 
      improved post-prandial and fasting hyperglycemia. They function by augmenting the 
      incretin system (GLP-1 and GIP) preventing their metabolism by dipeptidyl 
      peptidase-4 (DPP-4). Not only are they efficacious but also safe (weight neutral) 
      and do not cause significant hypoglycemia, making it a unique class of drugs. 
      This review focuses on gliptins (sitagliptin, vildagliptin, saxagliptin, 
      linagliptin, and alogliptin) discussing pharmacokinetics, pharmacodynamics, 
      efficacy, and safety.
FAU - Gupta, Vishal
AU  - Gupta V
AD  - Department of Endocrinology, Jaslok Hospital and Research Centre, 15 - Deshmukh 
      Marg, Mumbai 400026, India.
FAU - Kalra, Sanjay
AU  - Kalra S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC3193779
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - GLP
OT  - dipeptidyl peptidase-4-inhibitors
OT  - dipeptidyl-dipeptidase
OT  - gliptins
OT  - incretins
COIS- Conflict of Interest: None declared.
EDAT- 2011/10/27 06:00
MHDA- 2011/10/27 06:01
PMCR- 2011/10/01
CRDT- 2011/10/27 06:00
PHST- 2011/10/27 06:00 [entrez]
PHST- 2011/10/27 06:00 [pubmed]
PHST- 2011/10/27 06:01 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - IJEM-15-298 [pii]
AID - 10.4103/2230-8210.85583 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2011 Oct;15(4):298-308. doi: 10.4103/2230-8210.85583.